<DOC>
	<DOCNO>NCT00261573</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy galantamine ( drug treat dementia ) compare placebo treatment patient dementia relate cerebrovascular disease ( vascular dementia ) dementia relate Alzheimer 's disease cerebrovascular disease ( `` mix '' dementia ) .</brief_summary>
	<brief_title>A Study Safety Effectiveness Galantamine Versus Placebo Treatment Patients With Vascular Dementia Mixed Dementia</brief_title>
	<detailed_description>This multicenter , double-blind , placebo-controlled study evaluate safety effectiveness galantamine patient dementia relate cerebrovascular disease relate Alzheimer 's disease cerebrovascular disease ( `` mix '' dementia ) . All patient initially receive placebo 1-month period receive galantamine ( start low dose gradually increase 5 week 12 mg twice daily ) placebo 6 month . The primary measure effectiveness include change baseline end treatment ADAS-cog/11 score ( Alzheimer 's Disease Assessment Scale : sum 11 cognitive item ) CIBIC-plus score ( Clinician 's Interview Based Impression Change - Plus Caregiver Input ) . Additional measure effectiveness include change baseline end treatment ADAS-cog/13 score ( Alzheimer 's Disease Assessment Scale : sum 13 cognitive item ) , Disability Assessment Dementia ( DAD ) score , Neuropsychiatric Inventory ( NPI ) ) score . Safety evaluation ( incidence adverse event , electrocardiogram ( ECGs ) , physical examination , laboratory test ) perform throughout study . Patients complete double-blind portion study opportunity participate 6-month open-label extension study receive galantamine additional 6 month . Effectiveness assess 6 week , 3 month 6 month open-label treatment . Safety evaluation ( incidence adverse event , ECGs , physical examination , laboratory test ) perform throughout open-label portion study . The study hypothesis galantamine effective treatment patient vascular mixed dementia well tolerate . Double-blind : Galantamine 12 mg placebo mouth twice daily 6 month , start low dose gradually increase 5 week final dose ; Open-label : galantamine 12 mg mouth twice daily , start low dose gradually increase 6 week final dose .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Dementia , Vascular</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<criteria>Outpatients diagnosis vascular dementia accord NINDSAIREN International Workshop criterion diagnosis `` mixed '' dementia ( possible Alzheimer 's disease cerebrovascular disease ) accord NINCDSADRDA criterion mildtomoderate dementia ( score 10 25 Mini Mental Status Exam ( MMSE ) ADAScog score least 12 ) opportunity perform activity daily live ( dress , bathing , etc ) , include patient live independently residential home elderly onset disease age 40 90 consistent informant accompany schedule visit Neurogenerative disorder Parkinson 's disease cognitive impairment result condition acute cerebral trauma , cerebral damage due lack oxygen , vitamin deficiency , infection meningitis AIDS , significant endocrine metabolic disease , mental retardation , brain tumor significant psychiatric disease , active peptic ulcer , clinically significant liver , kidney lung disorder , heart disease history epilepsy , convulsion , drug abuse alcohol abuse females child bear potential without adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Alzheimer 's disease cerebrovascular disease ( `` mix '' dementia )</keyword>
	<keyword>probable vascular dementia</keyword>
	<keyword>galantamine</keyword>
</DOC>